Experience with Ceftriaxone in the Treatment of Pulmonary Infections

  • Faroque A Khan Division of Pulmonary Medicine, Queens Hospital Center, Jamaica, New York
  • Joseph J Guarneri Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
  • Rajinder Chitkara Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
  • Phyllis DellaLatta Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
  • Vincent LaBombardi Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
  • Pravez Mir Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
  • Suhail Raoof Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
Keywords: Ceftriaxone, Pulmonary Infection, cephalosporin, Cefoxitin

Abstract

DOI: http://dx.doi.org/10.5915/17-1-12717

This paper describes the experience with a new third generation cephalosporin, Ceftriaxone, in the treatment of 60 patients with bacterial pulmonary infection. The unique pharmacokinetics of Ceftriaxone allow its usage twice a day in contrast to the 4 to 6 times a day for comparable antibiotics, with potential cost savings. Administered twice a day the overall cure rate was 94% with no serious side effects. A brief review of the clinical application of Cephalosporins in the treatment of infections is included.

Presented at the 17th Annual Convention of the Islamic Medical
Association in St. Louis, Missouri, August 10-12, 1984

Author Biographies

Faroque A Khan, Division of Pulmonary Medicine, Queens Hospital Center, Jamaica, New York

M.D., FCCP, FACP

Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook

Joseph J Guarneri, Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
PhD
Rajinder Chitkara, Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
M.D., FCCP, FACP
Vincent LaBombardi, Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
PhD
Pravez Mir, Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
M.D.
Suhail Raoof, Division of Pulmonary Medicine, Department of Medicine, Division of Microbiology, Department of Laboratories, Queens Hospital Center Affiliation of the Long Island Jewish-Hillside Medical Center and School of Medicine. Health Sciences Center, State University of New York at Stony Brook
M.D.
Published
1985-01-12
Section
Original Articles